Tegafur, identified by CAS number 17902-23-7, stands as a cornerstone in the field of oncology, primarily serving as a chemotherapeutic prodrug. Its efficacy stems from its conversion into 5-fluorouracil (5-FU) within the body, a potent antineoplastic agent that targets and inhibits DNA synthesis. This makes Tegafur API a crucial component in the development of life-saving cancer treatments, particularly for gastrointestinal and colorectal cancers.

The demand for high-quality Tegafur API is continuously driven by advancements in pharmaceutical manufacturing technology and the increasing prevalence of cancer globally. As a leading supplier in China, NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing reliable access to this vital API. Our commitment ensures that pharmaceutical companies have the necessary resources to formulate effective and accessible cancer therapies. We understand the critical nature of oncology treatments and strive to uphold the highest standards in API production.

The mechanism of action of Tegafur involves its role as an antimetabolite. By interfering with thymidylate synthase, it disrupts the pyrimidine pathway, thereby halting the production of DNA. This targeted action makes Tegafur an invaluable tool in chemotherapy regimens, often used in combination with other drugs to enhance treatment outcomes. The pharmaceutical sector relies heavily on consistent and pure supplies of Tegafur API to develop various dosage forms, including oral and injectable medications.

For pharmaceutical companies seeking a dependable source, NINGBO INNO PHARMCHEM CO.,LTD. offers competitive pricing and rigorous quality assurance. Our strategic position as a manufacturer in China allows us to streamline production processes, reduce costs, and ensure that our clients receive API that meets stringent international standards. Partnering with us means securing a reliable supply chain for your critical oncology drug development needs.